These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 12197895)
21. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis. Hann SK; Kim JB Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004 [TBL] [Abstract][Full Text] [Related]
22. [Detection of serum autoantibodies against premelanosome protein 17 increases in the vitiligo patients]. Hu L; Sun L; Li Y; Li H; Liang D; Sun J; Wang X; Hu J; Xie X Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):411-3, 417. PubMed ID: 23643172 [TBL] [Abstract][Full Text] [Related]
23. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813 [TBL] [Abstract][Full Text] [Related]
24. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Yan S; Brennick JB Am J Surg Pathol; 2004 May; 28(5):596-600. PubMed ID: 15105646 [TBL] [Abstract][Full Text] [Related]
25. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes. Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530 [TBL] [Abstract][Full Text] [Related]
26. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells]. Höfs T Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826 [TBL] [Abstract][Full Text] [Related]
27. Autoimmune etiology of generalized vitiligo. Le Poole IC; Luiten RM Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889 [TBL] [Abstract][Full Text] [Related]
28. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128 [TBL] [Abstract][Full Text] [Related]
30. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. Kemp EH; Gawkrodger DJ; MacNeil S; Watson PF; Weetman AP J Invest Dermatol; 1997 Jul; 109(1):69-73. PubMed ID: 9204957 [TBL] [Abstract][Full Text] [Related]
31. Immunodetection of the MCHR1 antibody in vitiligo patient sera. Zhou M; Guan C; Lin F; Xu W; Fu L; Hong W; Wan Y; Xu A Int J Mol Med; 2011 May; 27(5):725-9. PubMed ID: 21369690 [TBL] [Abstract][Full Text] [Related]
32. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. Naughton GK; Eisinger M; Bystryn JC J Invest Dermatol; 1983 Dec; 81(6):540-2. PubMed ID: 6196421 [TBL] [Abstract][Full Text] [Related]
33. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo. Austin LM; Boissy RE Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691 [TBL] [Abstract][Full Text] [Related]
34. Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata. Kemp EH; Sandhu HK; Weetman AP; McDonagh AJ Br J Dermatol; 2011 Dec; 165(6):1236-43. PubMed ID: 21895622 [TBL] [Abstract][Full Text] [Related]
35. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. Norris DA; Kissinger RM; Naughton GM; Bystryn JC J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009 [TBL] [Abstract][Full Text] [Related]
36. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810 [TBL] [Abstract][Full Text] [Related]
37. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138 [TBL] [Abstract][Full Text] [Related]
38. Dysfunction of glutathione S-transferase leads to excess 4-hydroxy-2-nonenal and H(2)O(2) and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients. Kostyuk VA; Potapovich AI; Cesareo E; Brescia S; Guerra L; Valacchi G; Pecorelli A; Deeva IB; Raskovic D; De Luca C; Pastore S; Korkina LG Antioxid Redox Signal; 2010 Sep; 13(5):607-20. PubMed ID: 20070240 [TBL] [Abstract][Full Text] [Related]
39. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548 [TBL] [Abstract][Full Text] [Related]
40. Detection of antibodies to melanocytes in vitiligo by western immunoblotting. Hann SK; Shin HK; Park SH; Reynolds SR; Bystryn JC Yonsei Med J; 1996 Dec; 37(6):365-70. PubMed ID: 9048487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]